Cemiplimab-rwlc
ImmunotherapyApproved for: NSCLC NSCLC patients tumors with high PD-L1 expression and without EGFR, ALK, ROS1 aberrations. Related Research News Novel drug shows promise in early-stage ROS1 clinical trialsGSK hits go on pivotal TIM-3 lung cancer trial after phase 2...